Stem cells and osteoporosis therapy.
Skeletal remodeling requires recruitment of osteoblast precursors, in the form of MSCs, to the bone surface. In this issue of Cell Stem Cell, Wu et al. (2010) demonstrate that this event is mediated by osteoclastic mobilization of active transforming growth factor β1, which is inhibited by a common antiosteoporosis drug.
Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA. teitelbs@wustl.edu
Steven L
SL
Teitelbaum
D019386:Alendronate / Q000494:pharmacology; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000502:physiology; D010006:Osteoblasts / Q000502:physiology*; D010010:Osteoclasts / Q000187:drug effects*; D010024:Osteoporosis / Q000628:therapy*; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors*
D050071:Bone Density Conservation Agents; D053773:Transforming Growth Factor beta1; D019386:Alendronate